Results 141 to 150 of about 1,011,187 (267)

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

Integrated Multi-Omics Profiling Identifies PDZ-Binding Kinase (PBK) as a Novel Prognostic Biomarker in Hepatocellular Carcinoma

Journal of Hepatocellular Carcinoma
Juan Zhang,1,* Yingyu Xu,2,* Xiaojian Ni,2,* Zhiyi Mao,3,* Haitao Xiao,4 Maopei Chen,1 Youpei Lin,5 Jiaomeng Pan,5 Boheng Zhang,6 Lan Zhang,1 Xueying Zheng,3 Guohe Song,5 Ningling Ge1 1Department of Hepatobiliary Oncology,
Zhang J, Xu Y, Ni X, Mao Z, Xiao H, Chen M, Lin Y, Pan J, Zhang B, Zhang L, Zheng X, Song G, Ge N   +12 more
doaj  

The versatile interplay between steatotic liver disease and liver cancer. [PDF]

Nat Rev Cancer
Rahbari M, Gris-Oliver A, Ramadori P, Aicher D, Sia D, Malek NP, Loomba R, Bataller R, Llovet JM, Heikenwälder M.   +9 more
europepmc   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

Decision Conflict Faced by First-Degree Relatives of Liver Cancer Patients in Liver Cancer Screening: A Cross-Sectional Study in China. [PDF]

Patient Prefer Adherence
Zhang J, Xia J, Su N, Wu Y, Wang S, Tao X.   +5 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

A report from the Second Tanzania Liver Cancer Conference (TLCC) 2025 - leading the fight against liver cancer in Sub-Saharan Africa. [PDF]

Ecancermedicalscience
Mwanga AH, Justiniano J, Mbuguje EM, Musa B, Mwanakulya DB, Swallow A, Kimambo E, Uiso E, Pazi S, Rajab L, Kivuyo NE, Akoko L, Naif A, Ngaiza A, Nyagabona S, Ndumbalo J, Mwakigonja AR, Littlejohn JE, Wibonela S, Gaskill CE.   +19 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Management and outcomes of patients with liver cancer in China and the United States. [PDF]

Chin Med J (Engl)
Xu M, Geng Q, Shan T, Liu M, Chen J, Liu M, Han B, Xia C, Ran X, Sun K, Wang S, Shen Y, Chen R, Li L, Zhao H, Chen W, Lu L, Zhang Y, Zeng H.   +18 more
europepmc   +1 more source